welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
expertly curated content related to this topic
- Todd SpurrierThe mission of DESTINATION X RIDE (DXR) ...
- An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal SurgeryThis will be a prospective, multi-center...
- Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis PatientsThe purpose of this registry is to colle...
- An International Randomised Trial of Celecoxib versus Celecoxib plus Difluoromethylornithine in Patients with Famili...BACKGROUND AND AIM : Although Non-steroi...
- Iron infusionshttps://www.youtube.com/watch?v=OaFSmO4p...
- Prostanoids, Ornithine Decarboxylase, and Polyamines in Primary Chemoprevention of Familial Adenomatous PolyposisBACKGROUND & AIMS : Familial adenoma...
English
Portuguese
Spanish